Research programme: genetically modified tumour-infiltrating lymphocytes - PolyBioCept AB/Lion Biotechnologies

Drug Profile

Research programme: genetically modified tumour-infiltrating lymphocytes - PolyBioCept AB/Lion Biotechnologies

Latest Information Update: 17 Oct 2016

Price : $50

At a glance

  • Originator PolyBioCept
  • Developer Lion Biotechnologies Inc; PolyBioCept
  • Class T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 Sep 2016 Lion Biotechnologies and Karolinska University Hospital plan two phase I trials for Glioblastoma and Pancreatic cancer in Sweden
  • 15 Sep 2016 Lion Biotechnologies in-licenses tumour-infiltrating lymphocytes technology and patents from PolyBioCep
  • 15 Sep 2016 Preclinical trials in Cancer in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top